HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand

This article was originally published in The Pink Sheet

Executive Summary

US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.

You may also be interested in...

Industry Roundup: Warning Letters, DXM Bill, Nutrition Label Update

DXM age-restriction bill in Senate; Mosquito band marketer settles with FTC; and more news in brief.

DXM Sales Age Restriction Reaches Florida; CHPA Navigates PSE Road

Florida is the first of several states CHPA expects in 2016 will pass legislation banning sales of DXM-containing OTCs to minors. CHPA looks this year to support similar bills in Arkansas, Pennsylvania and Ohio while keeping an eye toward state activity on sales of PSE-containing OTCs.

To Curb PSE Diversion, Retailers Lead By Example With Emphasis On Tamper-Resistant Products

An HHS agency’s 2013 drug use survey shows the number of meth users rising by 155,000 after changing little the previous two years. Acura Pharmaceuticals notes the survey and Tennessee data showing that making only tamper-resistant, single-ingredient PSE products available affects the diversion rate.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts